Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

NCT00006269 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Diarrhea

Interventions

DRUG: irinotecan hydrochloride
DRUG: octreotide acetate

Sponsor

Novartis